The FDA has declined to approve the use of rivaroxaban to manage stroke and heart attack risk in patients with acute coronary syndrome, and the drug was also rejected for cutting the risk of stent thrombosis. In a separate move, an advisory panel has advised against approval of cangrelor to treat stent-related complications.

Related Summaries